Vascular remodelling and hypertrophy represent early therapeutic targets of antihypertensive treatment. The present study was aimed at assessing the effects of 1-year administration of the highly vasoselective calcium-channel blocker lercanidipine (10 mg/day) or the diuretic compound hydrochlorothiazide (25 mg/day) on hypertension-related vascular alterations. The study was also aimed at assessing whether and to what extent: (i) pharmacological regression of vascular hypertrophy is related only to the blood pressure (BP) reduction "per se" or also to the specific ancillary properties of a given drug and (ii) treatment provides restoration of vascular function indicative of normal vascular structure.
Grassi, G., QUARTI TREVANO, F., Scopelliti, F., Seravalle, G., Cuspidi, C., Mancia, G. (2006). Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes. BLOOD PRESSURE, 15(5), 268-274 [10.1080/08037050600963669].
Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes
GRASSI, GUIDO;QUARTI TREVANO, FOSCA ANNA LUISA;CUSPIDI, CESARE;MANCIA, GIUSEPPE
2006
Abstract
Vascular remodelling and hypertrophy represent early therapeutic targets of antihypertensive treatment. The present study was aimed at assessing the effects of 1-year administration of the highly vasoselective calcium-channel blocker lercanidipine (10 mg/day) or the diuretic compound hydrochlorothiazide (25 mg/day) on hypertension-related vascular alterations. The study was also aimed at assessing whether and to what extent: (i) pharmacological regression of vascular hypertrophy is related only to the blood pressure (BP) reduction "per se" or also to the specific ancillary properties of a given drug and (ii) treatment provides restoration of vascular function indicative of normal vascular structure.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
